An investigation for investors in NASDAQ:BCRX shares was announced over potential breaches of fiduciary duties by certain directors at BioCryst Pharmaceuticals.
Investors who purchased shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and currently hold any of those NASDAQ:BCRX shares have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain BioCryst Pharmaceuticals officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
BioCryst Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $17.33 million in 2013 to $13.61 million in 2014 and that its Net Loss increased from $30.11 million to $45.19 million
On October 8, 2015, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administeredBCX7353 in healthy volunteers successfully met all of its objectives. In a separate announcement BioCryst Pharmaceuticals, Inc. announced the completion of patient enrollment in OPuS-2: a Clinical Trial of Avoralstat in Patients With HAE. Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) declined from $16.39 per share to as low as $8.01 per share on October 8, 2015.
On February 8, 2016, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial ofavoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary angioedema (HAE) attacks. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) declined to as low as $1.63 per share on February 12, 2016.
On February 23, 2016, NASDAQ:BCRX shares closed at $1.90 per share.
Those who purchased NASDAQ:BCRX shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego